Disclaimer: This article has been developed and funded by Daiichi Sankyo ... in breast and lung cancer, two of the most common cancers and biggest killers in our society. Precision medicines ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

The trial showed an ORR of 62.6% for Enhertu compared to 34.4% for chemotherapy in HER2-low and HER2-ultralow metastatic breast cancer ... milestone payment to Daiichi Sankyo.

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of ...